ReNeuron Group plc (LON:RENE – Get Free Report) passed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of GBX 3.44 ($0.05) and traded as low as GBX 3.28 ($0.04). ReNeuron Group shares last traded at GBX 3.38 ($0.04), with a volume of 177,373 shares changing hands.
ReNeuron Group Price Performance
The stock has a market cap of £1.93 million, a price-to-earnings ratio of -37.50 and a beta of 0.83. The stock has a fifty day simple moving average of GBX 3.38 and a 200-day simple moving average of GBX 3.44. The company has a current ratio of 1.51, a quick ratio of 2.02 and a debt-to-equity ratio of 14.25.
About ReNeuron Group
ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate for treating stroke disability; and human retinal progenitor cell therapy that is in Phase 2 clinical trial for treating retinitis pigmentosa, a blindness-causing disease.
Featured Articles
- Five stocks we like better than ReNeuron Group
- The Role Economic Reports Play in a Successful Investment Strategy
- Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge
- Investing in Construction Stocks
- How the Fed’s Rate Cut Could Supercharge These 3 ETFs
- What Are Dividend Champions? How to Invest in the Champions
- Microsoft Stock: 3 Reasons It’s Ready to Crush Q4
Receive News & Ratings for ReNeuron Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ReNeuron Group and related companies with MarketBeat.com's FREE daily email newsletter.
